Clicky

Lexeo Therapeutics Inc. Common Stock(LXEO)

Description: Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.


Keywords:

Home Page: www.lexeotx.com

345 Park Avenue South
New York, NY 10010
United States
Phone: 212-547-9879


Officers

Name Title
Mr. R. Nolan Townsend CEO & Director
Dr. Eric Adler M.D. Chief Medical Officer & Head of Research
Ms. Jenny R. Robertson J.D. Chief Business & Legal Officer
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
Mr. Rand Monaghan Vice President of Finance
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer
Dr. Sandi See Tai M.D. Chief Development Officer
Mr. Ryan McHenry VP & Corporate Controller

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6927
Price-to-Sales TTM: 0
IPO Date: 2023-11-03
Fiscal Year End: December
Full Time Employees: 69
Back to stocks